#New York City #Israel #Investor #biotherapeutics #Protalix

Protalix BioTherapeutics to Attend Major Investor Conferences in September 2026

Protalix BioTherapeutics, Inc., a company publicly traded on the NYSE American under the ticker PLX, has announced its participation in two significant investor conferences scheduled for September 2026 in New York City. The company's Senior Vice President and Chief Financial Officer, Gilad Mamlok, will represent Protalix at these events, aiming to connect with potential investors and stakeholders.

Details of the Conferences

1. H.C. Wainwright 28th Annual Global Investment Conference
- Dates: September 14-16, 2026
- Presentation Date: September 14, 2026
- Time: 2:00 PM EDT

2. Morgan Stanley 24th Annual Global Healthcare Conference
- Dates: September 14-16, 2026
- Fireside Chat Date: September 16, 2026
- Time: 10:05 AM EDT

Investors and interested parties can tune into a live audio webcast of the fireside chat through the Morgan Stanley Events Calendar and will have access to an archived version afterward. This opportunity reflects Protalix’s commitment to transparency and investor engagement, allowing a thorough understanding of its operations and future projects.

About Protalix BioTherapeutics

Protalix is dedicated to the discovery, development, and commercialization of groundbreaking therapies targeting rare diseases that often lack effective treatment options. The company specializes in enzyme replacement therapies, having successfully developed and launched two notable products:

• - Elfabrio® (pegunigalsidase alfa-iwxj) for Fabry disease, with approval in various markets including the United States and the European Union, in partnership with Chiesi Global Rare Diseases.
• - Elelyso® (taliglucerase alfa) for Gaucher disease, which has received global approvals in 23 markets. For the Brazil market, Protalix collaborates with the Brazilian Ministry of Health's Fundação Oswaldo Cruz.

The company is currently working on multiple projects, including:

• - PRX-115, a recombinant PEGylated uricase aimed at managing uncontrolled gout, which is in the Phase 2 RELEASE trial.
• - PRX-119, designed to be a long-acting DNase I targeting diseases associated with Neutrophil Extracellular Traps (NETs).
• - Other research initiatives focusing on rare renal disorders.

Protalix sets itself apart by utilizing its proprietary plant cell-based expression system, ProCellEx®, to develop its therapeutics, which distinguishes it in the biopharmaceutical industry.

Upcoming Communications

For additional details regarding the conferences, or to arrange one-on-one meetings with the management team, interested parties are encouraged to reach out to their conference representatives. Protalix aims to provide comprehensive insights into its operational strategies and future directions, enhancing potential investor relations and fostering broader community interest in the innovative work being done within biopharmaceuticals for rare diseases.

Conclusion

The upcoming investor conferences present an exciting platform for Protalix BioTherapeutics to highlight its innovations, share strategic visions, and strengthen connections within the investing community. As they prepare for these significant events, the company remains focused on its mission to deliver transformative therapies that address unmet medical needs.